GENO CLUSTER
Global Business Opportunities Available for Replications
Key Regions
28 States, 9 Union Territories, G20 Countries, Global South Countries, Common Wealth Countries, SAARC Countries,
African Countries, MENA Countries, GCC Countries, Global FANA Embassies in 176 Countries
The Geno-Cluster platform software tool has achieved remarkable milestones in facilitating new drug discovery and vaccine development.Its accomplishments include:
Key Achievements
Identification of 283 proteins: : Patented using Seapath, enabling novel adhesin identification in SARS and 17 other pathogenic organisms..
Discovery of 4 new SARS virus genes: : Utilizing GeneDcfer, leading to the development of the CoVaxin vaccine..
Prediction of protein-coding regions: In 18 SARS-CoV strains, facilitating gene annotation using PLHOSTFA..
Functional signatures identification:For 2605 bacterial and 112 human hypothetical proteins, enhancing understanding of protein functions.
Novel adhesin identification: In SARS and other pathogenic organisms, enabling vaccine development using Reverse Vaccinology with Seapath.
Impact
CoVaxin vaccine development : The identification of 4 new SARS virus genes led to the invention of the CoVaxin vaccine.
200 crore doses administered : India successfully produced and administered 200 crore doses of the CoVaxin vaccine.
Contribution to global healthcare:Geno-Cluster's achievements have significantly contributed to global healthcare, particularly in the fight against COVID-19..
The Geno-Cluster platform has demonstrated its potential in accelerating vaccine development and drug discovery, and its impact will continue to be felt in the scientific community and beyond.
